News
Exactech Q3 Revenue $42.4M; Net Income $2.7M or $0.21 EPS
GAINESVILLE, Fla. – October 27, 2009 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that total revenue for the third quarter of 2009 increased 12% to $42.4 million from $37.9 million in the third quarter of 2008. Diluted earnings per share for the quarter was $0.21 based on net income of $2.7 million. This compares with net income of $2.1 million or $0.16 diluted EPS a year ago. Net income for the quarter, excluding pre-tax legal expenses and costs of $845,000 related to the ongoing Department of Justice (DOJ) inquiry, was $3.3 million or $0.25 EPS.
Exactech Named As One Of America's 200 Best Small Companies by Forbes.com
Exactech, Inc. (Nasdaq: EXAC), has been Ranked #188 on the list of America's 200 Best Small Companies published by Forbes.com.
Exactech Announces Q3 Earnings and Conference Call
GAINESVILLE, Fla. – Oct 15, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its third quarter earnings on Tuesday, October 27, after the market closes.
Exactech Team Wins Distinguished Technology Partnership Excellence Award
GAINESVILLE, Fla. – September 15, 2009 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the company has earned the Technology Partnership Award of Excellence from the Association for Operations Management (APICS).
Exactech Announces Participation at Upcoming Healthcare Investor Conferences
GAINESVILLE, Fla. -- September 2, 2009 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it will be participating at three major healthcare conferences during September. Exactech President David Petty and CFO Jody Phillips will be delivering presentations and meeting with investors at the following conferences:
Exactech to Present at CanaccordAdams Annual Global Growth Conference on August 11
GAINESVILLE, Fla. -- August 10, 2009 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced that Chairman and CEO Bill Petty will present at the CanaccordAdams 29th Annual Global Growth Conference in Boston on Tuesday, August 11 at 4:30 p.m. Eastern Time.
Exactech Q2 Revenue $43.3M; Net Income $2.6M or $0.20 EPS
GAINESVILLE, Fla. -- July 28, 2009 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that total revenue for the second quarter of 2009 decreased 1% to $43.3 million from $43.7 million in the second quarter of 2008. Diluted earnings per share for the quarter was $0.20 based on net income of $2.6 million. This compares with net income of $3.0 million or $0.24 diluted EPS a year ago. Net income for the quarter, excluding pre-tax legal expenses and costs of $1.2 million related to the ongoing Department of Justice (DOJ) inquiry, was $3.4 million or $0.26 EPS.
Exactech to Present at the 2009 Noble Financial Equity Conference on June 8
GAINESVILLE, Fla. -- June 1, 2009 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will present at the Fifth Annual Noble Financial Equity Conference in Hollywood, Florida. The two-day investor conference will showcase 140 small cap public companies.
Exactech Q1 Revenue Increases 9% to $43.3 Million
GAINESVILLE, Fla. -- April 29, 2009 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $43.3 million for the first quarter of 2009, a 9% increase over $39.8 million in the first quarter of 2008. Net income was $2.5 million, or $0.19 per diluted share, compared to $2.8 million, or $0.23 per diluted share, in the same quarter a year ago. Net income for the quarter, excluding pre-tax legal expenses and costs of $1.4 million related to the ongoing Department of Justice (DOJ) inquiry, was $3.3 million or $0.26 EPS.
Exactech Schedules First Quarter 2009 Earnings Release and Conference Call
GAINESVILLE, Fla. -- April 23, 2009 -- Exactech, Inc. (Nasdaq: EXAC,), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its first quarter financial results on Wednesday, April 29, 2009 after regular trading hours end. A copy of the earnings release will be available at http://www.hawkassociates.com.
Pro Golfer Peter Jacobsen Endorses Exactech Knee Following Successful Knee Replacement
GAINESVILLE, Fla. -- March 12, 2009 -- Exactech, Inc. (Nasdaq: EXAC,), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the company has partnered with professional golfer Peter Jacobsen to tell the story of his successful knee replacement with Exactech’s Optetrak® total knee system in 2008.
Exactech Receives Patent for Rotating Bearing Knee, Optetrak RBK System
GAINESVILLE, Fla. -- February 24, 2009 -- Exactech, Inc. (Nasdaq: EXAC,), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that is has been issued U.S. Patent 7,422,605,B2 for its rotating bearing knee prosthesis, Optetrak® RBK™.
Exactech to Present Growth Strategies at Canaccord Adams Musculoskeletal Conference in Conjunction With AAOS Orthopaedic Meeting
GAINESVILLE, Fla. -- February 23, 2009 -- Exactech, Inc. (Nasdaq: EXAC,), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, today announced its schedule of future events.
Exactech Extends Knee Development License with Hospital for Special Surgery
GAINESVILLE, Fla. -- February 23, 2009 -- Exactech, Inc. (Nasdaq: EXAC,), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it has extended its relationship with Hospital for Special Surgery, New York, NY, to further advance implant designs for total knee replacement surgery. Exactech plans to introduce a new knee implant as an evolution of its flagship Optetrak® brand, as a result of this continued collaboration. Limited release of the new knee is expected in the second half of 2009.
Exactech 2008 Revenue Up 30% to $162M; Net Income Up 31% to $11.1M, EPS $0.87
GAINESVILLE, Fla. -- February 18, 2009 -- Exactech, Inc. (Nasdaq: EXAC,), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that revenue for 2008 increased 30% to $161.7 million from $124.2 million in 2007. Diluted earnings per share for the year was $0.87 based on net income of $11.1 million. This compares with net income of $8.5 million or $0.72 diluted EPS a year ago. Net income for 2008 included pre-tax legal expenses and costs of $2.6 million related to the ongoing Department of Justice (DOJ) inquiry.
Exactech, Inc. Announces Year End Earnings and Conference Call
GAINESVILLE, Fla. -- Feb. 12, 2009 -- Exactech, Inc. (Nasdaq: EXAC,), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its fourth quarter and 2008 year-end earnings on Wednesday, February 18, 2009, after the market closes.
